Lv2
180 积分 2023-11-07 加入
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
1天前
待确认
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China (PACER-II): a phase 2, multicentre, randomised, double-blind, placebo-controlled trial
26天前
已完结
Surface area of the hand and digits
27天前
已完结
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
27天前
已完结
The pancreatic cancer drug market
27天前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
1个月前
已完结
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
1个月前
已完结
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
1个月前
已完结
CD47 as a potent target in cancer immunotherapy: A review
1个月前
已完结
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
1个月前
已完结
皖公网安备34019202002308
